Patrys’ CEO and MD, Dr James Campbell, spoke with Proactive’s Elisha Newell about the announcement of two new US patents for the Company’s novel deoxymab technology.
These patents provide protection for Patrys’ antibody technology until 2039.
Patrys’ CEO and MD, Dr James Campbell, spoke with Proactive’s Elisha Newell about the announcement of two new US patents for the Company’s novel deoxymab technology.
These patents provide protection for Patrys’ antibody technology until 2039.